Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited announced on Mar, 30 2026 that it plans to provide three joint-and-several guarantees totalling about 0.59 billion Singapore dollars (approximately 3.10 billion renminbi) for credit facilities to be raised in the financial year ending Dec, 31 2026.

The guarantees comprise:

• up to 0.27 billion Singapore dollars for credit lines of Tianjin Pharmaceutical Group Taiping Medicine Co., Ltd.; • up to 0.24 billion Singapore dollars for credit lines of Tianjin Zhongxin Medicine Co., Ltd. from third-party banks; and • up to 0.08 billion Singapore dollars for credit lines of Tianjin Zhongxin Medicine Co., Ltd. from Tianjin Pharmaceutical Group Finance Co., Ltd.

The guarantees will be given in proportion to Da Ren Tang’s 43.35 % stake in Taiping Medicine, with the remaining liability borne by controlling shareholder Tianjin Pharmaceutical Holdings Co., Ltd.

Based on the group’s latest audited net tangible assets of roughly 1.33 billion Singapore dollars as at Dec, 31 2025, the combined guarantee amount equals about 44 % of NTA, exceeding the 5 % threshold that requires approval from independent shareholders under Singapore Exchange rules.

The proposals were cleared by Da Ren Tang’s independent directors and will be tabled for shareholder approval at the company’s annual general meeting scheduled for May, 15 2026. No binding agreements have yet been signed with the lending institutions.

Shareholders and investors are advised to exercise caution when dealing in the company’s shares pending the AGM vote.